Eylea Hd Injection, Solution
Product Images NDC 61755-050

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Eylea Hd (NDC 61755-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Regeneron Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Eylea 01)

An instructional illustration showing two hands removing the cap from a vial. The vial is small and held securely with one hand, while the other hand grips the vial's top cap, preparing to lift it off. The image likely relates to the preparation or administration of an injectable solution.*

FDA Label Image

Figure 2 (Eylea 02)

An instructional illustration showing hands preparing a vial labeled as EYLEA HD (aflibercept) injection solution for intravitreal use. The image depicts one hand holding the vial while the other hand lifts the vial's cap, demonstrating part of the preparation process before administration.*

FDA Label Image

Figure 3 (Eylea 03)

An instructional illustration showing a person's hands preparing an intravitreal injection by removing a cap or seal from a syringe containing a solution. The image likely relates to the use of EYLEA HD (aflibercept) injection, solution, 8 mg/0.07 mL, made by Regeneron Pharmaceuticals, Inc.*

FDA Label Image

Figure 4a (Eylea 04)

An instructional black-and-white line drawing showing a gloved hand holding a vial while another gloved hand pulls solution from the vial into a syringe. This image illustrates the preparation steps for using EYLEA HD aflibercept injection, solution for intravitreal administration.*

FDA Label Image

Figure 4b (Eylea 05)

An instructional illustration showing proper technique for drawing solution into a syringe. The needle bevel is pointed down and immersed in the solution to prevent air bubbles before injection. The image emphasizes careful handling of the syringe and needle.*

FDA Label Image

Figure 5 (Eylea 06)

An instructional illustration showing a hand holding a syringe with the cap being removed from the needle. The image demonstrates the step of detaching the needle cap before use, likely for the EYLEA HD intravitreal injection, aflibercept 8 mg/0.07 mL.*

FDA Label Image

Figure 6 (Eylea 07)

An instructional illustration showing two hands preparing a syringe for injection, one hand holding the syringe with a visible dosage scale and the other hand poised nearby, likely demonstrating proper injection technique for an intravitreal injection.*

FDA Label Image

Figure 7a (Eylea 08)

Illustration showing a syringe with measurement markings from 0.1 to 0.3 mL. An arrow points to the 0.1 mL mark, highlighting the volume in the syringe likely used for intravitreal injection.*

FDA Label Image

Figure 7b (Eylea 09)

An instructional diagram showing a syringe with liquid medication marked with dose lines in milliliters. A close-up highlights the dose line for 0.07 mL, the flat plunger edge, and a note about ensuring solution clarity after expelling air bubbles and excess drug.*

FDA Label Image

Figure 8 (Eylea 10)

Line graph depicting mean change in visual acuity (letters) over 48 weeks for three groups labeled HDq12, HDq16, and 2q8, with respective sample sizes of 335, 338, and 336. The x-axis represents weeks, and the y-axis shows mean change in visual acuity, ranging from 0 to 15 letters. The data show increasing mean change over time, with 2q8 peaking at +7.6 letters by week 48.*

FDA Label Image

Figure 9 (Eylea 11)

Line graph showing mean change in visual acuity (letters) over 48 weeks for three treatment groups labeled HDq12, HDq16, and 2q8 with sample sizes 328, 163, and 167 respectively. The x-axis represents time in weeks and the y-axis indicates mean change in visual acuity from 0 to 15 letters. Final values at 48 weeks are approximately +9.2, +8.8, and +7.9 letters.*

FDA Label Image

Principal Display Panel (0.07 mL Vial Carton)

Packaging label for EYLEA HD (aflibercept) Injection, 8 mg (0.07 mL of a 114.3 mg/mL solution) for intravitreal injection. The carton includes one 8 mg/0.07 mL single-dose glass vial, needles for withdrawal and injection, a 1-mL syringe, and prescribing information. The labeler is Regeneron Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (0.07 mL Vial Carton)

EYLEA HD (aflibercept) Injection 8 mg (0.07 mL of a 114.3 mg/mL solution) intravitreal injection single-dose vial packaging label. The carton includes dosing and administration information, carton contents listing a single-dose glass vial and prescribing information, and the labeler name Regeneron Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.